Collegium Pharmaceutical, Inc (COLL) company profile
Close on Nov 12, 2026Market cap $812.26MP/E 24.9Yield –
About Collegium Pharmaceutical
Pharmaceutical Preparations, SIC 2834
Collegium Pharmaceutical, Inc. is a commercial-stage biopharmaceutical company that develops and markets medicines for serious conditions, specifically attention deficit hyperactivity disorder and pain management. The company’s portfolio includes Jornay PM, an evening-dosed central nervous system stimulant indicated for patients six years of age and older with ADHD, and Symproic for opioid-induced constipation. Its pain portfolio also includes prescription opioid analgesics such as Xtampza ER, Belbuca, and Nucynta extended-release and immediate-release formulations. The company distributes its prescription products primarily to wholesalers, which supply retail pharmacies, managed health care organizations, and government agencies.
Collegium commercializes its product portfolio within the United States through dedicated field sales teams, including a 105-person pain sales force and a 200-person ADHD sales team. Manufacturing and packaging operations for its drug products are conducted across various partner facilities situated throughout the United States, including locations in Wisconsin, Ohio, Pennsylvania, Minnesota, New Jersey, and Tennessee.
Summary of the business section of Collegium Pharmaceutical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Collegium Pharmaceutical, Inc
- Founded
- 2002
- Headquarters
- Stoughton, MA
- Address
- 100 Technology Center Drive 02072
- Phone
- (781) 713-3699
- Website
- www.collegiumpharma.com
- Employees
- 423, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Virginia
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- COLL
- Exchange
- Nasdaq
- IPO date
- May 7, 2015
- Shares outstanding
- 33M, Jul 31, 2026
- Public float
- $926.40M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1267565
- CUSIP
- 19459J104
- ISIN
- US19459J1043
- FIGI
- BBG000N7LPW4
- Share class FIGI
- BBG001T535S9
- LEI
- 54930049FXZMTLW8D496
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Vikram Karnani | President and CEO, Director | 176,629 |
| David Dieter | EVP & General Counsel | 68,231 |
| Scott Dreyer | EVP & Chief Commercial Officer | 75,329 |
| Thomas B. Smith | EVP and Chief Medical Officer | 85,312 |
| Colleen Tupper | EVP & Chief Financial Officer | 147,282 |
| Shirley R. Kuhlmann | EVP and General Counsel | 108,137 |
| Gino Santini | Director | 112,483 |
| John Gordon Freund | Director | 115,706 |
| Donovan Michael Glancy | Director | 17,482 |
| Nancy Lurker | Director | 26,758 |
| Garen G. Bohlin | Director | 71,000 |
| Carlos V. Paya | Director | 28,323 |
| Rita J. Balice-Gordon | Director | 61,370 |
| John A. Fallon | Director | 99,487 |
| Michael Thomas Heffernan | Director | 213,371 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.72M | $7.86M | $3.13M | $225 | $158 |
| FY2024 Ciaffoni | $10.69M | $36.48K | $2.95M | $139 | $118 |
| FY2024 Heffernan | $466.46K | $460.84K | $2.95M | $139 | $118 |
| FY2024 Karnani | $10.78M | $9.58M | $2.95M | $139 | $118 |
| FY2023 | $9.14M | $15.00M | $2.57M | $150 | $119 |
| FY2022 | $6.92M | $10.49M | $1.85M | $113 | $114 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Vikram Karnani President and Chief Executive Officer | $875.00K | – | $835.41K | $5.44K | $1.72M | -84% |
| Colleen Tupper Executive Vice President and Chief Financial Officer | $559.34K | $2.48M | $449.29K | $21.94K | $3.52M | +10% |
| David Dieter Executive Vice President and General Counsel | $384.62K | $3.19M | $277.18K | $18.56K | $3.87M | – |
| Scott Dreyer Executive Vice President and Chief Commercial Officer | $523.24K | $2.16M | $335.56K | $21.94K | $3.04M | +9% |
| Thomas Smith Executive Vice President and Chief Medical Officer | $492.96K | $1.62M | $315.20K | $17.54K | $2.45M | -2% |
| Shirley Kuhlmann Former Executive Vice President, Chief Administrative Officer, General Counsel and Secretary | $115.52K | $1.97M | – | $702.05K | $2.78M | -16% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- May 7, 2015
- Offer price
- $12.00
- Securities offered
- 5,800,000
- Gross proceeds
- $69.60M
- Exchange
- Nasdaq
- First trading day
- May 7, 2015
- First-day close
- $12.29+2.4%
- Lock-up ends (est.)
- Nov 3, 2015
“Per Share Total Initial public offering price $ 12.00 $ 69,600,000 Underwriting discounts and commissions (1) $ 0.84 $ 4,872,000 Proceeds, before expenses, to us $ 11.16 $ 64,728,000 (1) We refer you to "Underwriting" beginning on page 176 of this prospectus for additional information regarding total underwriter co”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 423 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 12, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 4, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 23, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 18, 2022 | Tender offer | Third-party tender offer for the company's shares |
| Feb 13, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 15, 2016 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 7, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| May 1, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?